Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003784 · ClinicalTrials.gov registry record · Phase 2
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00003784 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 102 participants.
The verdict
NCT00003784, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by monoclonal antibody therapy in treating patients who have newly diagnosed follicular non-Hodgkin's lymphoma.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG doxorubicin hydrochloride
- DRUG CHOP regimen
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 1999-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003784
The ClinicalTrials.gov registry entry for NCT00003784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00003784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003784 about?
NCT00003784 is a clinical study titled "S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without ha...
What is the current status of trial NCT00003784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 1999-05.
What interventions are being tested in trial NCT00003784?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), doxorubicin hydrochloride (DRUG), CHOP regimen (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003784?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.